Virginia Commonwealth University

VCU Scholars Compass
Psychiatry Publications

Dept. of Psychiatry

2013

Delayed Onset and Prolonged ECT-Related
Delirium
Sameer Hassamal
Virginia Commonwealth University, shassamal@mcvh-vcu.edu

Ananda Pandurangi
Virginia Commonwealth University, apandura@vcu.edu

Vasu Venkatachalam
Virginia Commonwealth University, vvenkatachalam@mcvh-vcu.edu

James Levenson
Virginia Commonwealth University, jlevenson@mcvh-vcu.edu

Follow this and additional works at: http://scholarscompass.vcu.edu/psych_pubs
Copyright © 2013 Sameer Hassamal et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.

Downloaded from
http://scholarscompass.vcu.edu/psych_pubs/1

This Article is brought to you for free and open access by the Dept. of Psychiatry at VCU Scholars Compass. It has been accepted for inclusion in
Psychiatry Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Hindawi Publishing Corporation
Case Reports in Psychiatry
Volume 2013, Article ID 840425, 4 pages
http://dx.doi.org/10.1155/2013/840425

Case Report
Delayed Onset and Prolonged ECT-Related Delirium
Sameer Hassamal,1 Ananda Pandurangi,1 Vasu Venkatachalam,1 and James Levenson2
1
2

Department of Psychiatry, Virginia Commonwealth University, P.O. Box 980710, Richmond, VA 23298, USA
Department of Psychiatry, Virginia Commonwealth University, P.O. Box 980268, Richmond, VA 23298, USA

Correspondence should be addressed to Sameer Hassamal; shassama@gmail.com
Received 18 June 2013; Accepted 4 August 2013
Academic Editors: E. Jönsson, C. Lançon, D. Matsuzawa, and J. Saiz-Ruiz
Copyright © 2013 Sameer Hassamal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Electroconvulsive therapy (ECT) is effective in the treatment of depression. Delayed post-ECT delirium is rare but can occur in a
small subset of patients with risk factors and in most cases resolves with the use of psychotropic medications. We report a unique
presentation of a patient who developed a delayed post-ECT delirium with fecal incontinence that commenced 24 hours after the
administration of ECT. The condition resolved spontaneously after 48 hours without the use of psychotropic medications.

1. Introduction
ECT is an important treatment for severe depression including medication refractory depressive symptoms, mania,
schizophrenia, and catatonia [1]. However, in the United
States, ECT is most commonly used for the treatment of
unipolar depression after multiple trials of psychotropic medications have failed to achieve either an adequate response
or remission [2]. Although the exact mechanism of action is
unknown, a variety of theories postulate that ECT increases
monoamine neurotransmitter availability, induces a release of
hypothalamic or pituitary hormones, and increases neurogenesis or synaptogenesis [3–5]. ECT has also been shown to
have anticonvulsant properties [6].
Cardiovascular complications are the most common
causes of morbidity and mortality following ECT [7, 8].
Other complications include headaches, muscle pain, fatigue,
and nausea [9, 10]. Anterograde and retrograde amnesia
are common ECT-related cognitive complaints [8]. Typically,
anterograde amnesia resolves within a few weeks whereas
retrograde amnesia is more persistent [8]. Both types of
amnesia are more common with bilateral stimulation, highintensity electrical dosage, and sinus waveform stimulus
[11–13]. Mild confusion is reported in about 40% of cases;
however, delirium is common following the first seizure or

in those with predisposing brain pathology such as white
matter lesions [9, 14, 15]. Additionally, patients taking lithium
or dopaminergic medications concurrently with ECT are at
an increased risk of delirium [16].
We present the case of a highly functional 41-year-old
Caucasian woman who developed a severe and prolonged
ECT-related delirium.

2. Case Presentation
Ms. XX, a 41-year-old Caucasian woman with no known
medical illnesses was diagnosed with unipolar major depressive disorder at the age of 27 years. The current episode
was her 3rd, lasted over 4 months, and had only partially
responded to psychotropic medications including the combination of lithium carbonate 300 mg twice a day, mirtazapine
15 mg daily, and venlafaxine XR 450 mg daily. Ms. XX had
also failed treatment with bupropion and augmentation
with methylphenidate and aripiprazole. She scored 31 on
the Montgomery-Åsberg Depression Rating Scale (MADRS)
indicating moderate to severe depression. ECT was considered since she had failed at least four trials of antidepressants
along with augmentation strategies and had become impaired
to the point she could not function at work. On the week of
ECT, mirtazapine was discontinued, and venlafaxine XR and
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lithium carbonate were tapered to 225 mg daily and 300 mg
daily, respectively.
Detailed neurological and physical examination before
ECT did not reveal any abnormality. Baseline investigations including a complete blood count and comprehensive
metabolic panel of electrolytes, glucose, liver, and renal functions were within normal limits. Electrocardiogram (EKG)
was normal. Ms. XX scored 30/30 on a Mini Mental Status
Examination (MMSE) indicating no cognitive deficits. Head
computed tomography (CT) and Electroencephalography
(EEG) were not performed.
Right unilateral brief pulse treatment at 25% was initiated
three times weekly using the Thymatron System IV. Prior
to each ECT session, etomidate 16 mg and succinylcholine
100 mg were administered (etomidate was chosen due to a
nation-wide shortage of methohexital which is the preferred
anesthetic at our institution). The seizure response was 76 and
48 seconds after the first and second treatments, respectively.
After the second ECT session, Ms. XX developed a mild
agitated confusional state, which resolved immediately after
receiving 2 mg of intravenous midazolam. There was no
persistence of agitation or confusion over the next 2 days.
On the 3rd ECT session, the energy was increased to 50% to
obtain a robust seizure response. After the third ECT session,
Ms. XX again developed an agitated state, which also resolved
immediately after 2 mg of intravenous midazolam. No other
cognitive side effects were detected on clinical interview,
and the patient was discharged home in a fully oriented
state.
As per the report of her husband, she rested at home and
was not confused or agitated the rest of the day. However, 24
hours after the third ECT session, she developed a delirium
consisting of confusion, disorientation, markedly increased
speech latency time, and fecal incontinence. The on-call
psychiatrist was contacted who recommended a visit to the
emergency room, but the husband decided to wait until
Monday to see the ECT team. On Monday, 72 hours after
the last ECT treatment, Ms. XX presented to the ECT psychiatrist. Examination confirmed a severe confusional and
disoriented state with minimal to no responses to questions.
There was no evidence of any restlessness or perceptual
disturbances such as illusions or hallucinations. She was
ambulatory without ataxia and with no evidence of any focal
deficits on neurological examination.
She was admitted to the inpatient psychiatric unit for
safety and further assessment. Investigations including serum
electrolytes, renal and liver functions, blood sugar, and head
CT scan were normal. The lithium level was <0.3 mEq/L, and
the RBC-lithium was <0.10 mEq/L. EEG showed intermittent
disorganization and slowing over both frontal and temporal regions suggestive of moderate bihemispheric dysfunction, which can be seen with both metabolic and epileptic
encephalopathies. The patient’s cognition started to improve
in the hospital 72 hours after the last ECT and 48 hours after
the onset of the confusional state, without the use of psychotropic medications. Cognition and behavior were assessed
to be at or near baseline, and she was discharged home after
24 hours of observation. Interestingly, her depression had
significantly improved as well.
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3. Discussion
The etiology of the patient’s delirium is unclear. Based on our
observations, it appears as though ECT induced a delayed
and prolonged confusional state that resolved spontaneously.
However, multiple factors may have played a role. The condition could have been secondary to the ECT; the combination
of ECT, lithium, and venlafaxine; an atypical reaction to
midazolam; or some combination of the above. It is not clear
why this occurred only after the third ECT rather than the
first or second treatments. On the other hand, the agitation
episodes after the first and second treatments could have
been harbingers of the delirium to come. A new neurological or metabolic delirium onset was considered unlikely
as the patient improved spontaneously and maintained an
improved cognitive (and mood) status at 2-week followup.
A Medline search revealed two recent cases describing a
similar delayed onset delirium after ECT. Both of these cases
described this presentation as a delirium [17, 18]. An interictal
delirium usually occurs after a prolonged period of disorientation following ECT or can even occur independently of
the post-ictal state [18, 19]. The most common risk factors
are older age, subcortical and basal ganglia lesions, heart
disease, Parkinson’s disease, and Alzheimer’s disease [20, 21].
Our patient did not have any of these risk factors. Two other
subtypes of delirium after ECT have been described. The
most common subtype is an acute post-ictal disorientation
characterized by a confusional state immediately after ECT
typically self-resolving in an hour [18, 22]. The third is a
post-ECT delirium highlighted by hyperactivity that usually
begins a few minutes after the seizure induced by ECT [17,
18, 23]. Most post-ECT delirium cases last less than an hour,
tend to occur during the initial ECT treatments especially
in those switched from unilateral to bilateral treatment, and
usually resolve spontaneously or after the administration
of diazepam, midazolam, barbituratesm, or droperidol [16,
18, 24]. Our patient’s presentation did not fit the above
scenarios. Devanand and colleagues found that the degree
of pretreatment agitation, anesthetic or succinylcholine dose,
number of ECT’s received, or mean seizure duration did not
predict those who would develop post-ictal excitement [24].
There is conflicting data regarding the safety of lithium
and ECT. Some studies have shown a neurotoxic interaction between lithium and ECT, and others have shown no
significant increase in the incidence of complications [25–
27]. Although both lithium and ECT can independently
produce a delirium, Penney et al. found that concurrent
lithium and ECT is associated with an increased incidence
of severe or prolonged confusion [26]. The administration of
lithium in close temporal relationship to ECT was associated
with an increased risk of a confusional state [26]. The
serum lithium level, diagnosis, number, and laterality of
ECT treatments were not associated with the development
of an acute confusional state [26]. The onset and duration
of this neurotoxic interaction are quite variable and may
begin from hours to days after ECT and typically resolve over
days to months [28, 29]. This synergistic neurotoxic effect
has been documented at lithium levels as low as 0.37 mEq/L
[30, 31]. El-Mallakh suggested that the neurotoxic interaction
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is most likely secondary to ECT-induced intracellular lithium
toxicity at normal serum lithium levels [32]. Additionally,
ECT increases the permeability of the blood brain barrier,
which in turn may lead to a faster entry of lithium ions
[33, 34].
The concomitant use of antidepressants and ECT is
controversial in terms of efficacy and adverse side effects
[35]. However, due to concern about adverse side effects,
the American Psychiatric Association Task Force on ECT
discourages the concomitant use of antidepressants and ECT
[36]. Concomitant use of venlafaxine and ECT has been
found to improve clinical outcomes but may worsen cognitive
side effects [35]. There have been no case reports of a
prolonged complicated delirium after the concomitant use of
venlafaxine and ECT.
There has been at least one case report documenting
serotonin syndrome during treatment with lithium and
venlafaxine in spite of normal lithium levels [37]. However,
our patient’s delirium occurred at lower doses of both drugs
than when she has been prior to ECT, making the presence of
serotonin syndrome is unlikely. However, neuroleptics were
stopped weeks before ECT administration. In our patient and
consistent with our own ECT preparation guidelines, a precautionary decrease in lithium dose by 50% was implemented
just prior to commencement of the ECT course. If lithium
played any role in the subsequent delayed delirium after the
3rd ECT, obviously the decrease in dose did not help.
Midazolam is an attractive agent for managing post-ictal
hyperactivity after ECT due to its rapid clinical effect, rapid
elimination half-life of 2 hours, and low toxicity profile [38,
39]. The mean dose is usually 1.5 ± 0.9 mg, although repeat
doses may be necessary in some patients [40]. The onset of
action is usually less than 90 seconds and the recovery time is
usually 45 ± 30 minutes but can vary substantially [40]. In a
clinical trial of 21 patients receiving midazolam for post-ictal
hyperactivity, midazolam was found to be safe in all patients
and effectively treated delirium in 20 of the 21 patients [40].
Liston did not report any cases of a prolonged complicated
delirium after administration of midazolam. However, midazolam can induce a paradoxical reaction with agitation and
confusion in less than 1% of all patients receiving midazolam
[41]. This paradoxical reaction occurs most commonly in
patients with psychiatric or personality disorders [42–44].
In a clinical trial of 58 patients receiving midazolam for
lower body surgery, Weinbroum and colleagues found that
the midazolam-induced paradoxical reaction begins 45–210
minutes after sedation is started and can be reversed with
flumazenil [45].
What is unique about our case is the de novo onset of
delirium more than 24 hours after the ECT and treatment
of a post-ictal confusional state with midazolam. Although
there are limited case reports describing delirium after ECT,
none of them describe fecal incontinence. Additionally, the
delirium resolved spontaneously without psychotropic medications. The unique presentation as well as the spontaneous
resolution of the delirium may represent a unique subtype of
interictal delirium after ECT. In our case, the combination
of lithium and venlafaxine as well as midazolam may have
contributed to this interictal delirium.
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In our case, the delirium resolved after 48 hours and
did not require the use of psychotropic medications. Some
case reports of interictal delirium have persisted and required
antipsychotics, benzodiazepines, and donepezil [18].

4. Conclusion
We present a case of a 41-year-old otherwise healthy individual with a medication unresponsive unipolar depression,
who developed a delayed onset delirium after the 3rd ECT
that resolved spontaneously after 48 hours, with a concurrent
improvement in the depression. No specific etiology could be
established. Recommendations regarding the use of specific
psychotropic medications such as lithium during ECT need
to be further investigated due to case reports of adverse
side effects. Risk factors, treatment guidelines, and clinical
outcomes regarding a prolonged interictal delirium after ECT
need to be further elucidated.
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